

Oral presentation

Open Access

## New approach for congenital CMV infection diagnosis in neonates: sensibility and specificity of CMV detection in dried blood spots

Marianne Leruez-Ville<sup>\*1,6</sup>, Christelle Vauloup-Fellous<sup>2</sup>, Sophie Couderc<sup>4</sup>, Sophie Parat<sup>3</sup>, Salima Oucherif<sup>3</sup> and Jean-François Magny<sup>5</sup>

Address: <sup>1</sup>Hôpital Necker-Enfants-malades, AP-HP, National Reference Center for Cytomegalovirus, Paris, France, <sup>2</sup>Hôpital Antoine Bèclère, AP-HP, Virologie, Clamart, France, <sup>3</sup>Hôpital Necker-Enfants malades, Maternité, Paris, France, <sup>4</sup>Hôpital de Poissy, Maternité, Poissy, France, <sup>5</sup>Institut de Puériculture, Néonatalogie, Paris, France and <sup>6</sup>Université Paris-Descartes EA 36-20, Paris, France

\* Corresponding author

from Fifth Dominique Dormont International Conference. Mother-to-child transmitted viral diseases: from transmission to children care Paris, France. 26–28 March 2009

Published: 22 July 2009

Retrovirology 2009, 6(Suppl 1):O12 doi:10.1186/1742-4690-6-S1-O12

This abstract is available from: <http://www.retrovirology.com/content/6/S1/O12>

© 2009 Leruez-Ville et al; licensee BioMed Central Ltd.

### Background

Detection of CMV DNA in DBS (Guthrie cards) has been proposed for neonatal diagnosis of CMV congenital infection.

### Objectives

To evaluate the in vitro sensitivity of 2 methods of CMV DNA detection in DBS. To evaluate the specificity and the sensitivity of these 2 methods for congenital CMV diagnosis in comparison to the gold standard method (CMV detection in urine).

### Methods

To study in vitro sensitivity, "test cards" were prepared with dilutions of pre-quantified whole blood samples. To study in vivo specificity and sensitivity, 215 neonates who had CMV congenital infection diagnosis done by PCR or culture in a urine sample collected in the first week of life were included prospectively. Forty-five of these neonates had positive CMV detection in their urine (by PCR (Necker, Poissy, Bèclère) or by rapid culture (IPP)). CMV DNA was detected in the Guthrie cards by 2 methods. Method 1 consisted of DNA extraction in a whole DBS with NaOH 0.32% lysis followed by QIAamp DNA Blood Mini Kit and amplification by an in house real time PCR in duplicate. Method 2 was a phenol/chloroform extraction of a whole DBS followed by amplification with the CMV PCR kit (Abbott, France).

### Results

The 95% sensitivity of the 2 methods was 4000 and 2000 copies/ml respectively. In neonates, sensitivity and specificity of method 1 were 100% (45/45) and 96.9% (160/165) when at least one duplicate was positive and 88.8% (40/45) and 100% (165/165) when the two duplicates were positive. Sensitivity and specificity of method 2 were 95.1% (39/41) and 97.5% (158/162) respectively. Results were discordant (negative detection in urine and positive PCR in DBS) in 8 cards from 8 different neonates (4 with method 1 and 4 with method 2), these false positive were not repeatable when retested. Mean viral load of the 8 false positive were 376 [280–500] and 31 [9–53] copies/ml with method 1 and method 2 respectively. In one case, the CMV PCR in DBS was repeatedly positive with the 2 methods, whereas it was negative in the urine at birth by rapid culture. This case was considered as a false negative of the rapid culture and was therefore excluded from the analysis.

### Conclusion

Sensitivity of CMV DNA detection in DBS was very high when PCR was done in duplicate. However, when only one duplicate was positive it could be a false positive result. Low positive results needed to be confirmed by a second testing. In these best conditions, we think that these 2 methods are sensitive and specific enough for neonatal diagnosis of CMV congenital infection and for retro-

spective diagnosis in children presenting with hearing loss.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

